The Regeneration Paradox in Liver Cancer: How Chronic Injury Transforms Healing into Carcinogenesis.

IF 10.5 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY
Liver Cancer Pub Date : 2026-06-25 DOI:10.1159/000550897
Chun-Nan Yeh, Miin-Fu Chen
{"title":"The Regeneration Paradox in Liver Cancer: How Chronic Injury Transforms Healing into Carcinogenesis.","authors":"Chun-Nan Yeh, Miin-Fu Chen","doi":"10.1159/000550897","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The liver presents a fundamental paradox: it possesses unparalleled regenerative capacity yet demonstrates exquisite cancer susceptibility under chronic injury, with 85-90% of hepatocellular carcinoma (HCC) arising from chronic liver disease. Despite decades of research, the field lacks a unifying framework explaining this contradiction.</p><p><strong>Summary: </strong>We propose that HCC arises not from regeneration failing but from regeneration succeeding too long. The identical molecular pathways that safely restore hepatic mass after acute injury become carcinogenic when activated for decades rather than weeks - duration determines destiny. Living donor hepatectomy (60% resection) demonstrates zero cancer risk despite maximal proliferation because activation lasts only 2-4 weeks. Conversely, chronic HCV infection triggers identical responses monthly for 25-30 years, yielding 40-60% cumulative HCC incidence. When regeneration persists chronically, seven corruptions progressively accumulate: division trap (mutational accumulation), selection engine (clonal expansion), memory lock (epigenetic cementing), physical prison (mechanical oncogenesis), immune betrayal (tolerance induction), termination failure (brake inactivation), and senescence trap (SASP-mediated promotion). These develop in parallel and interact synergistically. Clinical evidence validates stage-dependent reversibility: HCV cure at F0-F1 achieves >95% cancer prevention, while cure at F4 cirrhosis provides 70% risk reduction despite irreversible corruptions. Taiwan's HBV vaccination program demonstrates >80% cancer reduction sustained over 40 years when chronic injury is prevented entirely.</p><p><strong>Key messages: </strong>Duration of pathway activation - not pathway identity - determines whether regeneration remains safe or becomes carcinogenic. Understanding HCC pathways as regenerative pathways stuck \"ON\" enables rational therapeutic strategies through corruption-specific targeting. Early intervention prevents >95% of cancers; even late intervention at cirrhosis achieves 70% benefit. The regeneration paradox transforms HCC from mysterious misfortune into predictable consequence, enabling precision prevention and treatment.</p>","PeriodicalId":18156,"journal":{"name":"Liver Cancer","volume":" ","pages":""},"PeriodicalIF":10.5000,"publicationDate":"2026-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13451030/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Liver Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000550897","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The liver presents a fundamental paradox: it possesses unparalleled regenerative capacity yet demonstrates exquisite cancer susceptibility under chronic injury, with 85-90% of hepatocellular carcinoma (HCC) arising from chronic liver disease. Despite decades of research, the field lacks a unifying framework explaining this contradiction.

Summary: We propose that HCC arises not from regeneration failing but from regeneration succeeding too long. The identical molecular pathways that safely restore hepatic mass after acute injury become carcinogenic when activated for decades rather than weeks - duration determines destiny. Living donor hepatectomy (60% resection) demonstrates zero cancer risk despite maximal proliferation because activation lasts only 2-4 weeks. Conversely, chronic HCV infection triggers identical responses monthly for 25-30 years, yielding 40-60% cumulative HCC incidence. When regeneration persists chronically, seven corruptions progressively accumulate: division trap (mutational accumulation), selection engine (clonal expansion), memory lock (epigenetic cementing), physical prison (mechanical oncogenesis), immune betrayal (tolerance induction), termination failure (brake inactivation), and senescence trap (SASP-mediated promotion). These develop in parallel and interact synergistically. Clinical evidence validates stage-dependent reversibility: HCV cure at F0-F1 achieves >95% cancer prevention, while cure at F4 cirrhosis provides 70% risk reduction despite irreversible corruptions. Taiwan's HBV vaccination program demonstrates >80% cancer reduction sustained over 40 years when chronic injury is prevented entirely.

Key messages: Duration of pathway activation - not pathway identity - determines whether regeneration remains safe or becomes carcinogenic. Understanding HCC pathways as regenerative pathways stuck "ON" enables rational therapeutic strategies through corruption-specific targeting. Early intervention prevents >95% of cancers; even late intervention at cirrhosis achieves 70% benefit. The regeneration paradox transforms HCC from mysterious misfortune into predictable consequence, enabling precision prevention and treatment.

肝癌的再生悖论:慢性损伤如何将愈合转化为癌变。
背景:肝脏呈现出一个基本的悖论:它具有无与伦比的再生能力,但在慢性损伤下却表现出微妙的癌症易感性,85-90%的肝细胞癌(HCC)起源于慢性肝脏疾病。尽管经过数十年的研究,该领域仍缺乏一个统一的框架来解释这一矛盾。总结:我们认为肝癌的发生不是由于再生失败,而是由于再生成功的时间过长。在急性损伤后安全地恢复肝脏肿块的相同分子途径在被激活几十年而不是几周后变成致癌物质——持续时间决定命运。活体供肝切除术(60%切除)显示,尽管增殖最大,但癌症风险为零,因为激活仅持续2-4周。相反,慢性丙型肝炎病毒感染在25-30年内每月引发相同的反应,累积HCC发病率为40-60%。当再生长期持续时,七种破坏逐渐累积:分裂陷阱(突变积累)、选择引擎(克隆扩展)、记忆锁(表观遗传巩固)、物理监狱(机械性肿瘤发生)、免疫背叛(耐受性诱导)、终止失败(制动失活)和衰老陷阱(sasp介导的促进)。这些都是并行发展并协同作用的。临床证据证实了阶段依赖的可逆性:HCV在F0-F1级治愈可实现95%的癌症预防,而F4级治愈可使肝硬化风险降低70%,尽管存在不可逆的腐败。台湾的乙肝疫苗接种计划表明,在完全预防慢性损伤的情况下,40多年来癌症减少了80%。关键信息:通路激活的持续时间——而不是通路的特性——决定了再生是安全还是致癌。将HCC通路理解为“ON”的再生通路,可以通过腐败特异性靶向制定合理的治疗策略。早期干预可以预防95%的癌症;即使是肝硬化晚期干预也能达到70%的疗效。再生悖论将HCC从神秘的不幸转变为可预测的后果,使精准预防和治疗成为可能。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Liver Cancer
Liver Cancer Medicine-Oncology
CiteScore
20.80
自引率
7.20%
发文量
53
审稿时长
16 weeks
期刊介绍: Liver Cancer is a journal that serves the international community of researchers and clinicians by providing a platform for research results related to the causes, mechanisms, and therapy of liver cancer. It focuses on molecular carcinogenesis, prevention, surveillance, diagnosis, and treatment, including molecular targeted therapy. The journal publishes clinical and translational research in the field of liver cancer in both humans and experimental models. It publishes original and review articles and has an Impact Factor of 13.8. The journal is indexed and abstracted in various platforms including PubMed, PubMed Central, Web of Science, Science Citation Index, Science Citation Index Expanded, Google Scholar, DOAJ, Chemical Abstracts Service, Scopus, Embase, Pathway Studio, and WorldCat.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书